Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
This longitudinal study offers an unprecedented look at the temporal changes in CSF and imaging biomarkers over two decades, providing clinicians with a detailed timeline of biomarker alterations that precede the clinical onset of Alzheimer’s disease, thereby paving the way for potential early diagnostic and therapeutic strategies.
Neurology March 5th 2024
Psychiatrist.com
Recent findings underscore the importance of addressing sedentary behavior in older adults as an independent risk factor for dementia, highlighting a significant opportunity for interventions focused on lifestyle modifications.
Geriatrics February 21st 2024
MDLinx
Recent studies suggest a potential link between sildenafil and other ED medications and a lower risk of developing dementia, emphasizing the importance of further clinical trials to explore these preliminary observations.
Clinical Pharmacology February 21st 2024
Practical Neurology
Explore the groundbreaking diagnostic capabilities of the p-tau217 test in Alzheimer’s disease, demonstrating high accuracy in detecting pathological markers and offering a new horizon in non-invasive diagnostic strategies.
Neurology February 6th 2024
Medical News Today (MNT)
A groundbreaking study in The Lancet Neurology reports that 94% of patients with posterior cortical atrophy also have Alzheimer’s disease pathology, stressing the need for heightened awareness among clinicians for earlier diagnosis and intervention.
This study uncovers a critical connection between contaminated pituitary-derived hormone treatments and the subsequent development of early-onset Alzheimer’s disease, highlighting the necessity for stringent safety protocols in medical treatments.